Mega Genomics Limited (HKG:6667)

Market Cap	1.63B -21.0%
Revenue (ttm)	151.45M -13.5%
Net Income	38.72M +10.8%
EPS	0.18 +6.9%
Shares Out	224.30M
PE Ratio	40.04
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	6,550
Open	n/a
Previous Close	7.26
Day's Range	n/a
52-Week Range	5.98 - 8.33
Beta	0.97
RSI	52.14
Earnings Date	Mar 31, 2026

About Mega Genomics

Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing, a service and ancillary service ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 203
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6667

Financial Performance

In 2024, Mega Genomics's revenue was 164.23 million, an increase of 8.54% compared to the previous year's 151.30 million. Earnings were 45.05 million, an increase of 49.96%.

Financial numbers in CNY